Clinical Trial Update: Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating the efficacy and safety of ofatumumab in Relapsing Multiple Sclerosis patients in China has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2025-11-12